Pfeifle C E, Howell S B
Cancer Treat Rep. 1983 Dec;67(12):1127-9.
A combination of hydroxyurea (HU) and cytarabine (ara-C) can overcome ara-C resistance in vitro. To determine the pattern of toxicity of this combination, 22 patients with refractory leukemia and lymphoma were treated for 5 days with ara-C (100 mg/m2/day by constant infusion) and escalating doses of HU (0.375-1.77 g/m2 every 6 hours). Hematologic toxicity was severe even at the lowest HU dose level. Skin and mucosal toxic effects were frequent but not dose-limiting. No novel types of toxic effects were observed.
羟基脲（HU）和阿糖胞苷（ara-C）联合使用可在体外克服对ara-C的耐药性。为确定该联合用药的毒性模式，对22例难治性白血病和淋巴瘤患者给予ara-C（持续输注，100 mg/m²/天）和递增剂量的HU（每6小时0.375 - 1.77 g/m²）治疗5天。即使在最低的HU剂量水平，血液学毒性也很严重。皮肤和黏膜毒性效应很常见，但并非剂量限制性的。未观察到新类型的毒性效应。
